Jinzhong
Jinzhong
Jinzhong, Shanxi, China6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-04-24 | NCT06536868 | |
| Intervention to Reduce Sedentary Behavior During School Recess Among Adolescents | Adolescents; Physical Activity; School-based Intervention; Sedentary Behaviour | Active, not recruiting | Not applicable | 2026-03-05 | NCT07451535 | |
| Normobaric Oxygen in AIS Transferred for EVT | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2025-12-11 | NCT06666764 | |
| A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests | Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Hepadnaviridae infectious disease, Infections, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, portal hypertension, viral hepatitis, viral infectious disease | Not yet recruiting | Not stated | 2025-07-25 | NCT07087041 | |
| Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2025-07-24 | NCT06157502 | |
| TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-01-07 | NCT05461339 |